Candel Therapeutics Reports Extended Survival Tail Observed in Trial of Aglatimagene Besadenovec (CAN-2409) in Advanced Non-Small Cell Lung Cancer Patients with Inadequate Response to Immune Checkpoin
Go back to Candel Therapeutics Reports Extended Survival Tail Observed in Trial of Aglatimagene Besadenovec (CAN-2409) in Advanced Non-Small Cell Lung Cancer Patients with Inadequate Response to Immune Checkpoin| (NASDAQ: CADL) | Delayed: 9.83 -0.05 (0.51%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $9.88 | 52 Week High | $ | |||
| Open | $9.97 | 52 Week Low | $ | |||
| Day High | $10.17 | P/E | N/A | |||
| Day Low | $9.57 | EPS | $ | |||
| Volume | 1,550,102 | |||||
